$21MSeries A, 23 March 2026
Emerged from stealth with a $21M Series A tranche to fund its Phase Ib/IIa Parkinson's trial, naming Ron Cohen CEO.
- Amount
- $21M
- Stage
- Series A
- Announced
- 23 March 2026
- Lead
- Neuro.VC
- Other investors
- Byers Capital
- Use of funds
- Emerged from stealth with a $21M Series A tranche to fund its Phase Ib/IIa Parkinson's trial, naming Ron Cohen CEO.
- Checked
- Announced by the company
- Sources
- Oryon Cell Therapies emerges from stealth with $21M for Parkinson's cell therapy businesswire.com
Oryon Cell Therapies emerges from stealth with $21M for Parkinson's cell therapy finance.yahoo.com